Product Description
Important lessons regarding relapse and its prevention and treatment were learned from managing chronic hepatitis C virus (HCV) infections with monotherapy. It now appears that some of these lessons may be applicable with combination therapy. In addition, many clinicians and investigators now question whether these other populations, such as interferon nonresponders, might also benefit from combination therapy. In Read more
Important lessons regarding relapse and its prevention and treatment were learned from managing chronic hepatitis C virus (HCV) infections with monotherapy. It now appears that some of these lessons may be applicable with combination therapy. In addition, many clinicians and investigators now question whether these other populations, such as interferon nonresponders, might also benefit from combination therapy. In part two of this 2-part series, you'll learn about state-of-the-art management strategies for relapsers and nonresponders. The important role of the primary care physician in managing hepatitis C is also examined.
